Screener
Viking Therapeutics VKTX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Viking Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Viking Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 29, 2026, 9:50 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-193315
| Revenues | Three Months Ended March 31, 2026 / — | Three Months Ended March 31, 2025 / — |
|---|---|---|
| Total other income, net | 5,800 | 9,840 |
| Net loss | (158,325) | (45,629) |
| Other comprehensive loss, net of tax: | ||
| Unrealized (loss) gain on securities | (1,250) | 563 |
| Foreign currency translation gain | 16 | 9 |
| Comprehensive loss | $(159,559) | $(45,057) |
| Basic and diluted net loss per share | $(1.37) | $(0.41) |
| Weighted-average shares used to compute basic and diluted net loss per share | 115,568 | 112,069 |
Item 1. Financial Statements
FAQ
- What is Viking Therapeutics's EPS (diluted)?
- Viking Therapeutics (VKTX) reported EPS (diluted) of -$1.37 in Q1 2026.
- How has Viking Therapeutics's EPS (diluted) changed year-over-year?
- Viking Therapeutics's EPS (diluted) decreased by 234.1% year-over-year, from -$0.41 to -$1.37.
- What is the long-term trend for Viking Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Viking Therapeutics's EPS (diluted) has grown at a 45.1% compound annual growth rate (CAGR), from -$0.72 to -$3.19.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Viking Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude